generation run 2026-05-11
55 min completedmodel pipeline-v5plan not recordedrun/c85aadc2…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
1 further caveat recorded as free text — readable on the working page
Reproduce
- inputs
- 17 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
19 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | ClinicalTrials.gov · absence | delta-11-tetrahydrocannabinol | 0 | 0 | No clinical trials registered for this compound |
| 2 | PubMed | delta 9,11-THC cannabinoid activity isomer | 3 | 3 | Key papers on receptor binding, conformation, and cardiovascular effects of delta-9,11-THC |
| 3 | PubMed | delta-11-tetrahydrocannabinol pharmacology | 15 | 4 | Direct primary research on delta-11-THC / delta-9,11-THC pharmacology and metabolism |
| 4 | PubMed | 9,11-tetrahydrocannabinol cannabinoid | 15 | 2 | Relevant to semi-synthetic market context and analytical detection of delta-9,11-THC |
| 5 | PubChem | delta-11-tetrahydrocannabinol | 1 | 1 | Primary chemical identity source; confirms exocyclic double bond structure |
| 6 | OpenAlex | delta-11-tetrahydrocannabinol | 10 | 0 | No directly relevant results for delta-11-THC specifically |
| 7 | WebFetch | — | 1 | 1 | Establishes legal framework applicable to delta-9,11-THC as a synthetic or semi-synthetic THC isomer |
| 8 | PubMed | synthesis delta-9(11)-trans-tetrahydrocannabinol 1971 | 1 | 1 | First synthesis paper for delta-9,11-THC (1971) |
| 9 | WebSearch | delta-9,11-THC delta-11-THC legal status DEA Schedule I controlled substance | 10 | 0 | General legal framework only - no compound-specific ruling found |
| 10 | PubMed | 9,11-tetrahydrocannabinol OR delta-9,11-THC agonist activity mice dogs monkeys 1987 | 1 | 1 | Most comprehensive animal pharmacology study of delta-9,11-THC |
| 11 | WebSearch | delta-9,11-THC UK Misuse of Drugs Act Australia Canada EMCDDA | 10 | 0 | General regulatory framework; no compound-specific rulings for delta-9,11-THC |
| 12 | WebSearch | delta-11-THC 11-hydroxy-THC confusion nomenclature isomer cannabinoid | 10 | 0 | Critical flag for generation agent about consumer market misinformation |
| 13 | PubMed | cannabinoid C9 substituent orientation activity structure 1989 | 1 | 1 | Key structure-activity paper explaining why delta-9,11-THC is inactive or weakly active at CB1 |
| 14 | PubChem REST API | — | 1 | 3 | Authoritative chemical structure data for the research output |
| 15 | Crossref DOI verification | 10.1021/jo00804a024 | 1 | 1 | Confirms first synthesis paper for the compound |
| 16 | WebSearch | EMCDDA novel cannabinoid THC isomers early warning Europe scheduling | 10 | 0 | Establishes EU regulatory context |
| 17 | WebSearch | delta-11-THC consumer market products effects potency claims | 10 | 0 | Establishes contemporary market context and important consumer misinformation flag |
| 18 | PubChem REST API - synonyms | — | 1 | 2 | Complete chemical registry data for the compound |
| 19 | Multiple sources | delta-11-THC vs 11-OH-THC nomenclature confusion | 5 | 0 | Critical flag for generation agent: claims of extreme potency are based on compound confusion |
120 claims by section — every cited sentence, checked against its source
pharmacology24 · 0 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
safety22 · 0 ok
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
history18 · 2 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Simultaneously, Reggio and colleagues at the University of North Carolina used molecular mechanics calculations to classify Δ-9,11-THC as an "inactive cannabinoid" based on its carbocyclic ring conformation, while Kriwacki and Makriyannis at the University of Connecticut characterized its solution conformation by NMR and similarly described it as "biologically inactive"supported
Molecular mechanics calculations show that carbocyclic ring conformation determines orientation relative to phenyl group hydroxyl. pmid:2738895
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
This regulatory framework inadvertently created a commercial pathway for semi-synthetic cannabinoids — compounds produced by isomerizing hemp-derived cannabidiol (CBD) into various THC isomerssupported
Current large-scale manufacture of HHC is based on hemp-derived CBD extract, converted by cyclization into delta8/delta9-THC mixture, followed by catalytic hydrogenation to afford a mixture of (9R)-HHC and (9S)-HHC epimers. dta.3519
summary14 · 0 ok
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
comparative-pharmacology10 · 1 ok
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Reggio et al. (1989) demonstrated that the chair conformation misaligns the C9 substituent relative to the phenolic hydroxyl, disrupting a geometric relationship proposed as critical for cb1-receptor binding.supported
Molecular mechanics calculations show that carbocyclic ring conformation determines orientation relative to phenyl group hydroxyl. pmid:2738895
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
pharmacokinetic-detail10 · 0 ok
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
chemistry8 · 0 ok
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
receptor-pharmacology8 · 1 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Reggio et al. (1997) synthesized O,2-propano-bridged analogs of Δ-9,11-THC and found modest CB2 selectivity in these derivatives, but the parent compound itself was not characterized at CB2.partially supported
HHC analogs evaluated for CB1 and CB2 receptor affinity. O,2-propano-9-beta-OH-11-nor-HHC: Ki(CB1) = 26 nM, Ki(CB2) = 5.8 nM. pmid:9379452
neuroscience6 · 0 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →